Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ
Closed
Aug 21, 2026
Day's Range
228.3452 wk Range
197.81Overview - ALNY - Alnylam Pharmaceuticals Inc
Key Statistics
Valuation
Enterprise Value
31.28B
P/E (Trailing)
‪41.15‬
P/E (Forward)
‪18.76‬
PEG Ratio
‪-0.12‬
Price / Sales (TTM)
‪6.57‬
Price / Book
‪23.33‬
EV / EBITDA
‪29.67‬
Profitability
Gross Margin
‪76.88%‬
Profit Margin
‪16.12%‬
Operating Margin
‪17.92%‬
Return on Assets
‪12.34%‬
Return on Equity
‪96.55%‬
Ownership
Shares Outstanding
133.73M
Float
133.23M
Short % of Shares Outstanding
‪4.78%‬
Held by Insiders
‪0.18%‬
Held by Institutions
‪101.71%‬
Price stats
Beta
‪0.27‬
50-Day Avg
‪266.65‬
200-Day Avg
‪331.03‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
28 analysts
Average price target
‪$ 370.20‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ALNY - Alnylam Pharmaceuticals Inc
Peers - ALNY - Alnylam Pharmaceuticals Inc
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - ALNY - Alnylam Pharmaceuticals Inc
About
Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root causes of diseases at the genetic level, offering potential treatments for rare and prevalent conditions across multiple…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
